John Clarke
Direktor/Vorstandsmitglied bei ATYR PHARMA, INC.
Vermögen: 31 576 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Paul Schimmel | M | 83 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | 22 Jahre |
Sanjay Shukla | M | 52 | 8 Jahre | |
Yvonne Greenstreet | M | 61 | 8 Jahre | |
John J. Park | M | - |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | 27 Jahre |
Tim Coughlin | M | 57 | 7 Jahre | |
Amy Schulman | F | 63 | 10 Jahre | |
Phillip Sharp | M | 79 | 22 Jahre | |
Michael Bonney | M | 65 | 10 Jahre | |
James Bradley | M | - |
Cureatr, Inc.
Cureatr, Inc. Packaged SoftwareTechnology Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | 6 Jahre |
Akshay Vaishnaw | M | 61 | 18 Jahre | |
Jesse E. Ambrosina | M | - |
Ivenix, Inc.
Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 12 Jahre |
Leslie Nangle | M | - | - | |
Jorgen Bundgaard Hansen | M | 57 |
Ivenix, Inc.
Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 4 Jahre |
Christine Regan Lindenboom | F | 43 | 9 Jahre | |
David Pyott | M | 70 | 9 Jahre | |
Joseph Mayer | M | - |
Cureatr, Inc.
Cureatr, Inc. Packaged SoftwareTechnology Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | - |
Nancy Krueger | F | 56 | 10 Jahre | |
Jane Gross | M | 67 | 5 Jahre | |
Kevin Fitzgerald | M | 56 | 19 Jahre | |
Svetlana Lucas | M | 52 | 5 Jahre | |
Ashlee Dunston | F | - | 4 Jahre | |
Richard Resnick | M | - |
Cureatr, Inc.
Cureatr, Inc. Packaged SoftwareTechnology Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | 7 Jahre |
Sara Nochur | M | 63 | 18 Jahre | |
Sara Zaknoen | M | 65 | 3 Jahre | |
Timothy J. Maines | M | - | 7 Jahre | |
Kent S. Marquardt | M | - |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | 6 Jahre |
Margaret Hamburg | M | 68 | 5 Jahre | |
Dennis Ausiello | M | 78 | 12 Jahre | |
Tom McKinley | M | 72 |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | 16 Jahre |
Colleen Reitan | F | 64 | 6 Jahre | |
Ian D. Fier | M | - | 22 Jahre | |
Pushkal Garg | M | 56 | 10 Jahre | |
Robert W. Ashworth | M | - | 3 Jahre | |
Nigam Shah | M | - |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Todd Pietri | M | - |
Cureatr, Inc.
Cureatr, Inc. Packaged SoftwareTechnology Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | 11 Jahre |
Vasant Jadhav | M | - | 10 Jahre | |
Bharath Ganesan | M | - |
Cureatr, Inc.
Cureatr, Inc. Packaged SoftwareTechnology Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | - |
Jim Glasheen | M | - |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Danielle Campbell | F | - | 3 Jahre | |
Kristin Anne Torres Mowat | F | - |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Muthiah Manoharan | M | - | 21 Jahre | |
Steven A. Bossone | M | - | 14 Jahre | |
George W. Gray | M | - |
Ivenix, Inc.
Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 13 Jahre |
Ketan Patel | M | 49 |
Ivenix, Inc.
Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | - |
John M. Douglass | M | - |
Ivenix, Inc.
Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 12 Jahre |
Diego Miralles | M | 62 |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
John J. Sokolowski | M | - |
Ivenix, Inc.
Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | 13 Jahre |
Wei Li | M | 52 |
Ivenix, Inc.
Ivenix, Inc. Medical SpecialtiesHealth Technology Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA. | - |
Alexa von Tobel | F | - |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
James Bilotta | M | - | 9 Jahre | |
Arnold Milstein | M | - |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Alan Eisenberg | M | - | 7 Jahre | |
Jill Broadfoot | F | 63 | 6 Jahre | |
Richard Heyman | M | 66 | - | |
Jo-Ann Beltramello | F | - | 17 Jahre | |
Peter L. Masanotti | M | 69 |
Cureatr, Inc.
Cureatr, Inc. Packaged SoftwareTechnology Services Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY. | - |
R. Alan B. Ezekowitz | M | 70 |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | - |
Lisa Carey | F | - | 9 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Christoph H. Westphal | M | 56 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 9 Jahre |
Craig Wheeler | M | 63 | 14 Jahre | |
John Mendlein | M | 64 | 9 Jahre | |
Marsha Fanucci | F | 70 | 18 Jahre | |
John Maraganore | M | 60 | 19 Jahre | |
Bruce Downey | M | 76 | 11 Jahre | |
Mike Mason | M | 49 | 14 Jahre | |
Amir Nashat | M | 51 | - | |
Susanna High | F | 56 | 9 Jahre | |
Grove Matsuoka | M | - | - | |
Dinah Sah | M | 63 | 7 Jahre | |
Elizabeth Stoner | M | 73 | 13 Jahre | |
Brandon H. Hull | M | 63 |
CHP Management, Inc.
CHP Management, Inc. Investment ManagersFinance CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey. | 20 Jahre |
Young Kwon | M | 52 | 10 Jahre | |
Marcy Graham | F | 57 | - | |
Thomas Paul Koestler | M | 71 | 9 Jahre | |
David Sinclair | M | 55 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Patricia Allen | F | 62 | 7 Jahre | |
Jeffrey Hatfield | M | 66 | 4 Jahre | |
David-Alexandre C. Gros | M | 51 | 2 Jahre | |
John Blake | M | 47 | 3 Jahre | |
Stan Blackburn | M | 68 | - | |
Peter Elliott | M | 64 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | - |
Steven Paul | M | 73 | 12 Jahre | |
Ben Shapiro | M | 84 | 13 Jahre | |
Richard Pops | M | 62 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 Jahre |
Barry Greene | M | 60 | 17 Jahre | |
Laurie Keating | F | 70 | 7 Jahre | |
Lisa Carron Shmerling | F | 63 | - | |
Manmeet Singh Soni | M | 46 | 2 Jahre | |
James Blair | M | 84 | 10 Jahre | |
James Sulat | M | 73 | 11 Jahre | |
Richard H. Aldrich | M | 69 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 Jahre |
Ram Sasisekharan | M | 58 | 9 Jahre | |
Peter Hutt | M | 89 | 13 Jahre | |
Bruce A. Leicher | M | 68 | 10 Jahre | |
Kevin Starr | M | 61 | 15 Jahre | |
Richard Shea | M | 72 | 13 Jahre | |
Robert Langer | M | 75 | 8 Jahre | |
Peter Barrett | M | 71 | 5 Jahre | |
Srini Akkaraju Akkaraju | M | 56 | 3 Jahre | |
Arianna Greco | M | - | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John Clarke
- Persönliches Netzwerk